Gynecologic oncologyHumansFemalePaclitaxelAlbuminsOvarian Neoplasms
Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS).
Mark S Shahin, Raina Mathur, Anju Parthan, Prakirthi Yerram, Amanda Kesner-Hays, Rachel Myers, Iulia Cristina Tudor, Darin Dobler, Adrian M Jubb, Robert L Coleman
Published: 202610.1016/j.ygyno.2025.11.022
Abstract
OBJECTIVE: To compare the real-world effectiveness and safety of monotherapy nab-paclitaxel and paclitaxel in patients with platinum-resistant ovarian cancer (PROC). METHODS: COMPASS is a retrospective, observational study using deidentified patient…
Preview only. Read the full abstract at the source